(168 days)
D-20 continuous non-invasive arterial oxygen saturation and pulse rate monitoring of for patients between 10 and 50 kg
I-20: continuous non-invasive arterial oxygen saturation and pulse rate monitoring of for patients between 3 and 20 kg
The ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor® II and Reprocessed Nellcor™ I-20 Oxysensor II are accessory devices to an oximeter monitoring system. The oxisensor is designed as a transducer for the transmission of electrical signals from the oximeter to the patient and the return of patient modified signals back to the oximeter for analysis and display of patient information. The sensor contains three optical components; two light emitting diodes (LEDs) serve as light sources and one photodiode acting as a light detector LED and sensor are contained in a laminated envelope provided with an adhesive bandage for attachment a patient. A sensor package is attached to a cable terminated in a multi-pin connector that plugs into the oximeter.
The provided text is a 510(k) summary for ReNu Medical Reprocessed Nellcor™ D-20 and I-20 Oxysensors. It describes the device, its intended use, and claims substantial equivalence to predicate devices based on bench testing, clinical performance data, and non-clinical performance data. However, this document does not contain the specific acceptance criteria or the detailed study results that prove the device meets those criteria.
Here's an analysis of what information is and isn't present, according to your request:
1. A table of acceptance criteria and the reported device performance
- Not provided. The document states that "ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor II and Reprocessed Nellcor™ I-20 Oxysensor® II function in a manner that is Substantially Equivalent to that of the predicate devices" based on various tests, but it does not specify what performance metrics were measured, what the acceptance criteria for those metrics were, or the actual results obtained in a table format.
2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Not provided. The document mentions "clinical performance data" but does not specify the sample size used for any test set or the provenance of the data (e.g., country of origin, retrospective/prospective nature).
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Not applicable/Not provided. This document describes a reprocessed medical device (oximeter sensor). For such devices, "ground truth" typically refers to engineering specifications met through bench testing or direct comparison to existing validated devices, rather than expert interpretation of medical images or diagnostic outputs. There is no mention of experts or their qualifications for establishing ground truth.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not applicable/Not provided. Similar to point 3, adjudication methods are typically relevant for studies involving human interpretation (e.g., radiologists reviewing images). This document does not describe such a study design.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- Not applicable. This device is an oximeter sensor, not an AI-powered diagnostic tool for human readers. Therefore, an MRMC study comparing human reader performance with or without AI assistance is irrelevant and not mentioned.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
- Not applicable. This device is a sensor, not an algorithm. The concept of "standalone algorithm performance" doesn't apply. The performance would be that of the sensor itself, typically measured through engineering and clinical validation studies as described under "bench testing, clinical performance data, and non-clinical performance data." However, the details of these studies are not provided.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- Implied ground truth through substantial equivalence. The document implies that the ground truth for the reprocessed sensors' performance is established by demonstrating that they function "Substantially Equivalent" to the original, legally marketed predicate devices (Nellcor™ D-20 Oxysensor® II and Nellcor™ I-20 Oxysensor® II). This would involve comparing the reprocessed devices' measurements (SpO2, pulse rate accuracy) against the known, validated performance of the predicate devices under various conditions. The specific "type" of ground truth would be the validated performance specifications of the predicate devices achieved through their original clinical and bench testing.
8. The sample size for the training set
- Not applicable/Not provided. This document describes a reprocessed hardware device, not a machine learning algorithm that requires a "training set."
9. How the ground truth for the training set was established
- Not applicable. As above, there is no "training set" for this type of device.
In summary: The provided document is a regulatory submission focused on demonstrating substantial equivalence of a reprocessed medical sensor to its predicate device. It lacks the detailed study results and specific acceptance criteria that would typically be found in a comprehensive clinical or performance study report. The information required in your prompt primarily pertains to studies involving diagnostic algorithms or human interpretation of medical data, which is not the subject of this 510(k) summary.
{0}------------------------------------------------
Section 13 Premarket Notification
510 (k) Summary
MAY 2 5 2007
Submitters Name and Address: ReNu Medical 9800 Evergreen Way Everett, WA 98024 9820 4 Phone: 425-353-1110 Fax: 425-353-9116
FDA Registration Number: 3034520
Contact Person: L. Bruce Pierson Chief Operating Officer
Date Summary Prepared: August 15, 2006
Trade or Proprietary Name(s): ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor" II. ReNu Medical Reprocessed Nellcor 10 I-20 Oxysensor" II
Common Name: Oxisensor
Classification: Oximeter (21 CFR 870.2700)/ NLF
Equivalent Device(s)
The ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor8 II and Nellcor™ I-20 Oxysensor II are substantially equivalent to the Nellcor™ D-20 Oxysensor® II and Nellcor™ I-20 Oxysensor8 II (respectively)
Device Description:
The ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor® II and Reprocessed Nellcor™ I-20 Oxysensor II are accessory devices to an oximeter monitoring system. The oxisensor is designed as a transducer for the transmission of electrical signals from the oximeter to the patient and the return of patient modified signals back to the oximeter for analysis and display of patient information. The sensor contains three optical components; two light emitting diodes (LEDs) serve as light sources and one photodiode acting as a light detector LED and sensor are contained in a laminated envelope provided with an adhesive bandage for attachment a patient. A sensor package is attached to a cable terminated in a multi-pin connector that plugs into the oximeter.
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows a handwritten number, "1063661". The numbers are written in a simple, slightly slanted style. The handwriting appears to be clear and legible.
Intended Use
Both the ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor® II and Reprocessed Nellcor™ 1-20 Oxysensor8 II are intended as single patient use O2 transducer/accessory sensors for use in conjunction with the Nellcor™ Oximeter system. The Model D-20 is used for infants from 10 to 50 kg. The Model I-20 is used for infants from 3 to 20 Kg. Both sensors are used for non-invasive monitoring of pulse oxygen hemoglobin saturation (SpO2) and pulse rate.
Technological Characteristics of the ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor II and Reprocessed Nellcor M 1-20 Oxysensor II Compared with the Nellcor M D-20 Oxysensor II and Nellcor M I-20 Oxysensor® II
The predicate devices and the ReNu Medical Reprocessed devices contain identical components (LED, photodiode, laminated envelope, cable, and connector.) The means of patient attachment (adhesive bandage) is identical.
Summary of Comparison Tests
Based on an assessment consisting of bench testing, clinical performance data, and non-clinical performance data the ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor II and Reprocessed Nellcor™ I-20 Oxysensor® II function in a manner that is Substantially Equivalent to that of the predicate devices.
Safety and Standards
The ReNu Medical Reprocessed Nellcor™ D-20 Oxysensor® II and Reprocessed Nellcor™ 1-20 Oxysensor $11 are designed to meet the following safety standards.
- EN 60601-1 �
- EN60601-1-2 .
- Biocompatibility ISO10993-10 1995 EN 30993-1
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the seal of the Department of Health and Human Services (HHS). The seal is circular and contains the words "DEPARTMENT OF HEALTH AND HUMAN SERVICES USA" around the perimeter. In the center of the seal is a stylized representation of three human figures, which are meant to symbolize the department's mission of protecting the health of all Americans.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. L Bruce Pierson Chief Operating Officer ReNu Medical, Incorporated 9800 Evergreen Way Everett, Washington 98204
MAY 2 5 2007
Re: K063661
Trade/Device Name: ReNu Reprocessed Nellcor Oxysensor, D-20 and I-20 Regulation Number: 870.2700 Regulation Name: Oximeter Regulatory Class: II Product Code: NLF Dated: May 22, 2007 Received: May 23, 2007
Dear Mr. Pierson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Eederal Register.
{3}------------------------------------------------
Page 2 - Mr. Pierson
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Soyite y. Michael DMD.
Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known): _____________
Device Name: ReNu Reprocessed Nellcor D-20 AND I -20 Oxysensor
Indications for Use:
D-20 continuous non-invasive arterial oxygen saturation and pulse rate monitoring of for patients between 10 and 50 kg
I-20: continuous non-invasive arterial oxygen saturation and pulse rate monitoring of for patients between 3 and 20 kg
Prescription Use _____________________________________________________________________________________________________________________________________________________________ (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Center for Devices and Radiological Health / CDRH
ා වියුග-ටිෆ්) tion of Anesthesiology, General Hospital, Scion Control, Dental Devices
MK) Number: K06366/
§ 870.2700 Oximeter.
(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).